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Studies of the cytochrome P450 arachidonic acid (AA)
monooxygenase, now established as a major pathway for the
bioactivation of this physiological important fatty acid, have
uncovered new and important roles for this enzyme system
in the regulation of kidney function, including renal
hemodynamics and tubular ion transport. Associations
between genetically controlled alterations in blood pressure
and the activity and/or transcriptional regulation of the
kidney Cyp2c AA epoxygenases and Cyp4a x-hydroxylases
revealed a role for these enzymes in the pathophysiology of
hypertension, a leading cause of cardiovascular, cerebral, and
renal morbidity and mortality. Furthermore, analysis of
associations between genetic variants of human CYP4A11
and hypertension suggest a potential role for this gene as a
determinant of polygenic blood pressure control in humans.
These results are providing conceptually novel approaches
for studies of the molecular basis of human hypertension
that could lead to new strategies for the early diagnosis and
clinical management of this devastating disease.
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Cytochrome P450s (P450) are best known for their roles in
the metabolism of toxic chemicals, drugs, and endogenous
substrates, such as steroids and cholesterol.1,2 More recently,
evidence has accumulated suggesting a functional role for
these enzymes as participants in the arachidonic acid (AA)
metabolic cascade.3–9 P450s belong to a complex superfamily
of genes with a common evolutionary origin, centered around
a conserved peptide that provides them with a cysteine heme
ligand and the ability to deliver an active form of atomic
oxygen to ground state carbons.1,2,6,10 Several mammalian
P450s are expressed in a gender-, age-, and organ-specific
manner, and their levels are regulated by hormones, cytokines,
diet, fasting, drugs, or are altered during the course of
diseases, such as obesity, diabetes, and hypertension.11–13
Based on nucleotide sequence identity, P450s are organized
into gene families (X40% identity) and subfamilies (X60%
identity), with approximately 57 genes identified in the
human genome.10 The biochemical, biophysical, and struc-
tural properties of these enzymes, as well as their pharma-
cological and toxicological roles have been extensively
documented.1,2,10 In contrast, our knowledge of the physio-
logical and/or pathophysiological significance of these pro-
teins is still limited. Ongoing studies of the roles of P450 in
AA bioactivation in water and electrolyte homeostasis and
systemic blood pressure control are providing new avenues for
the definition of their functional significance and roles in
renal physiology and pathophysiology.
The P450 AA monooxygenase catalyzes the nicotinamide
adenine dinucleotide phosphate-dependent oxidation of the
fatty acid to four regioisomeric epoxyeicosatrienoic acids
(EETs)(5,6-, 8,9-, 11,12-, and 14,15-EET)(AA epoxygenase
branch) and/or 19- and 20-hydroxyeicosatetraenoic acids
(19- and 20-HETE)(AA o hydroxylase branch)3,6,7 (Figure 1).
The identification of EETs and 20-HETE, as products of the
in vivo metabolism of AA by rodent and human tissues,3,4,6,7
established the AA monooxygenase as a formal metabolic
pathway, and suggested a biological role for its metabolites.3–9
After a slow start, the list of the citations dealing with
different aspects of the AA monooxygenase system has grown
significantly, with nearly 1200 PubMed (http://www.ncbi.
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nlm.nih.gov) citations in the last 10 years. Efforts to identify
the P450 isoforms responsible for these reactions were
complicated by the complexity of the enzyme system in
which, different proteins can share significant sequence
homology, metabolize AA to similar products, and, in many
cases, show common immunological determinants.3,6,10 It is
now accepted that members of the CYP2C and CYP4A gene
subfamilies are the predominant and functionally relevant
kidney AA epoxygenases and o-hydroxylases, respec-
tively3,4,6–9 (Figure 1). However, roles for CYP2J and CYP4F
isoforms as AA epoxygenase and o-hydroxylases, respectively,
have been reported.14,15
The synthesis of most P450 AA metabolites facilitated
their functional analysis, and generated an extensive list of
in vitro biological activities suggestive of a functional role for
the P450s involved in their biosynthesis.4,5,8,9 Many of these
studies have targeted the kidney since: (a) AA and its
metabolites have long documented roles in renal function;
(b) the early reports of the effects of EETs and 20-HETE on
distal sodium reabsorption and the activity of the kidney
Naþ /Kþ -ATPase, respectively,3–6,8 were suggestive of an
involvement in blood pressure regulation;4 (c) the organ
shows high CYP4A and CYP2C expression, and in vivo EET
and 20-HETE biosynthesis;3–6 (d) kidney offered an oppor-
tunity to correlate P450 expression with the nephron
functional segmentation;4,5 and (e) available animal models
of kidney dysfunction permitted associations between renal
function and P450 expression and/or enzymatic activity.3–6,8
It was this type of an approach that led John McGiff and
collaborators to suggest a role for the renal AA monooxy-
genase in the pathophysiology of experimental hyperten-
sion.4,16 This original proposal opened new opportunities to
study the physiological and/or pathophysiological signi-
ficance of the P450 AA pathway, and has served as a powerful
stimuli for some of the most important advances in this area.
From insightful integrations of the functional responses to
P450 metabolites and correlations between their biosynthesis,
the expression of CYP4A and CYP2C isoforms and blood
pressure changes in rodent models of genetically controlled
hypertension, pro- and anti-hypertensive roles were proposed
for the products of the AA o-hydroxylase and epoxygenase,
respectively.4,16 Notwithstanding the clinical importance of
hypertension, this proposal offered novel approaches for
studies of the molecular basis of this disease, and it identified
kidney dysfunction and blood pressure as distinct end point
phenotypes for studies of the functional consequences of
genetic and/or experimental manipulations of P450 expres-
sion and/or enzyme activity.
PRO- AND ANTI-HYPERTENSIVE ROLES FOR 20-HETE
HAVE BEEN IDENTIFIED IN RAT MODELS OF GENETICALLY
DETERMINED HYPERTENSION
In spontaneously hypertensive rats (SHR rats), blood
pressure increases between 5 and 10 weeks of age while,
under identical conditions, comparable (but not isogenic)
Wistar–Kyoto rats remain normotensive. Based on: (a) bio-
chemical and temporal correlates of kidney CYP4A AA o-
hydroxylase expression and activity with the development of
hypertension in SHR rats;4,16 (b) the prevention of
hypertension in SHR rats by SnCl2-mediated depletion of
renal P450s;4,16 (c) the normotensive effects of SnCl2
administration to hypertensive SHR animals,4,16 and
(d) the functional effects of 20-HETE,4–6,8,16 a pro-hypertensive
role was identified for the CYP4As and 20-HETE.4,5,8,16
Subsequently, anti-sense nucleotide inhibition of gene
expression identified CYP4A1 and 4A2 as the pro-hyperten-
sive 20-HETE synthases in the rat kidney.17 In agreement
with its proposed pro-hypertensive action, 20-HETE was
shown to be a potent, in vitro, renal vasoconstrictor,4,5,8 and
to inactivate smooth muscle calcium-sensitive Kþ channels.5
Furthermore, 20-HETE is formed by vascular smooth muscle
cells,18 and it potentiates the activity of vasoconstrictors, such
as angiotensin II, endothelin, and serotonin.18 In contrast,
studies with the Dahl rat model of salt-sensitive hypertension
identified an anti-hypertensive role for 20-HETE and
CYP4A2 based on: (a) the in vitro natriuretic properties of
20-HETE;5 (b) CYP4A inhibitor studies;5 (c) differences
between Dahl salt-sensitive (DS) and salt-resistant rats (DR)
in the expression of CYP4A2 and 20-HETE biosynthesis;5
and (d) normalization of Cl transport in DS rats by
20-HETE.5 Furthermore, CYP4A inducers have normotensive
effects on DS rats and on sexually immature Sprague–Dawley
rats.5,19 This apparent duality in CYP4A2 and 20-HETE
functional role illustrates the importance that the nephron
segment-specific expression of selected P450 isoforms is likely
a determinant of physiological and/or pathophysiology
significance. Lastly, roles for angiotensin II on renal AA
metabolism and EET and 20-HETE biosynthesis, as well as
for these eicosanoids in the renal and vascular effects of the
hormone have been reported.5,20–24
ANTI-HYPERTENSIVE ROLE FOR THE EETs HAS BEEN
IDENTIFIED IN A RAT MODEL OF SALT-SENSITIVE
HYPERTENSION
The inhibition of distal sodium reabsorption and potassium
excretion by EETs,25 and the upregulation of the rat kidney
CYP2C23 epoxygenase expression and urinary EET excretion
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Figure 1 | Reactions catalyzed by cytochrome P450 AA
monooxygenases.
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by excess dietary salt intake26 pointed to an anti-hypertensive
role for the AA epoxygenase and the EETs.3–8 Furthermore: (a)
inhibition of the rat kidney epoxygenase reduces urinary EET
levels, and induces salt-sensitive hypertension;27 and (b) on a
high salt diet, Dahl salt-resistant rats increase their renal EET
biosynthesis and remained normotensive, whereas, under
similar conditions, salt-loaded DS rats show comparably lower
EET biosynthetic activity, and develop severe salt-sensitive
hypertension.27 In contradistinction to 20-HETE4,5,8 and in
support of their anti-hypertensive roles, the EETs were shown
to participate in the bradykinin-induced, endothelium-depen-
dent dilation of the afferent arteriole.28 The EETs activate
vascular smooth muscle calcium-sensitive Kþ channels,29,30
and 11,12-EET has been identified as an endothelium-derived
hyperpolarizing factor (EDHF).9,29,30 Moreover, EET synthesis
and release from endothelial cells is stimulated by vasodilators,
such as methacholine and bradykinin.30 Among the EETs,
11,12-EET is the most active renal vasodilatory epoxide, and
the predominant regioisomer generated by a rat CYP2C23
present in isolated renal microvessels.28 These facts under-
scored some of the anti-hypertensive properties identified for
the CYP2C epoxygenase pathway, as well as their relevance to
the kidney responses to changes in dietary salt intake.
Studies with the SHR/Wistar–Kyoto and Dahl salt-
resistant/DS rat models of genetic hypertension yielded
several important correlations between selected AA epoxy-
genase and o-hydrolase isoforms, renal function, and
systemic blood pressure.3–5,8,16 However, the circumstantial
nature of these associations, the questionable selectivity of
many of the inhibitor approaches reported,3–5,16,27 and the
complexity and multi-genetic nature of the animal models
studied precluded unequivocal interpretations of the accu-
mulated data and thus, the role(s) of P450 in blood pressure
regulation remained uncertain, and mostly unrecognized. On
the other hand, advances in gene-targeting techniques have
facilitated their application and, in the last few years, gene
disruption has become a method of choice for studies of
gene-determined phenotypes and the analysis of physiologi-
cal roles.31–33 Although not without some limitations, the
unsurpassed selectivity of these methods has contributed to
the uncovering of the function, mechanism of action, and the
pathophysiological roles of an increasing number of genes
and encoded proteins.
Based on the extensive list of biological activities
attributed to 20-HETE, including pro-hypertensive proper-
ties,4,5,8,16 the limited number of murine Cyp4a isoforms,10,34
and the roles reported for the CYP4A 20-HETE synthases in
SHR hypertension,4,16 the murine Cyp4a gene subfamily was
selected to initiate the development of monogenic models of
P450 dysfunction. The mammalian CYP4A proteins show
high degrees of sequence and functional evolutionary
conservation, and the rat and mouse proteins share extensive
sequence identity (Figure 2).10 The murine Cyp4a gene
subfamily is composed of three highly homologous genes,
Cyp4a10, Cyp4a12, and Cyp4a14 (Figure 2),10,34 and two
additional pseudo-genes (not transcribed or coding for non-
functional proteins).10 All three Cyp4a genes are expressed in
the male kidney, although Cyp4a12 is nearly undetectable in
the female kidney.34,35 Studies with recombinant proteins
showed that Cyp4a12 is an active AA o-hydroxylase, Cyp4a10
shows a substantially lower activity, and Cyp4a14 is
inactive.35–37 Prior publications also demonstrated the initial
phenotype characterization of the knockout mice by disrup-
tion of the Cyp4a10 and Cyp4a14 genes by non-homologous
recombination with targeting vectors in which segments of
the genes coding sequences were deleted.35,36 It is of interest
that both Cyp4a14(/) and Cyp4a10(/) mice are
hypertensive, although the mechanisms involved in their
hypertensive phenotypes are quite different.35,36 Paradoxi-
cally, in both these models, the targeted genes are not directly
responsible for the hypertensive phenotypes but rather, they
control the expression of surrogate pro- or anti-hypertensive
P450 genes.35,36 Moreover, these studies further illustrated
the importance that organ/tissue-specific expression and
transcriptional regulation have as key determinants of the
physiological and/or pathophysiological roles played by AA
epoxygenases and o-hydroxylase and their metabolites.
DISRUPTION OF THE MURINE Cyp4a14 GENE CAUSES
SEXUALLY DIMORPHIC, ANDROGEN-SENSITIVE
HYPERTENSION
Phenotypic analysis of Cyp4a14(/) mice showed that adult
male mice were hypertensive (Figure 3a), whereas comparable
females showed a less severe phenotype (mean arterial blood
pressures of 14573 and 11572 for male and female
Cyp4a14(/) mice, respectively. nX20).35 These earlier
results provided direct evidence of a role for the P450 enzymes
in the regulation of systemic blood pressure.35 The sexual
dimorphic nature of this phenotype suggested a role for sex
hormones in Cyp4a14(/) hypertension, a suggestion
confirmed after castration and/or androgen administration.35
Castration lowered blood pressure of male Cyp4a14(/)
mice (Figure 3a),35 and testosterone or 5a-dihydroxy-testos-
terone administration restored the hypertensive phenotype of
castrated Cyp4a14(/) mice.35 Importantly, these androgens
raised blood pressure, regardless of mouse gender or Cyp4a14
genotype,35 and had similar, pro-hypertensive, effects when
administered to rats.38 A more detailed study of Cyp4a14
(/) mice showed that the gene disruption raised male
plasma androgens levels, upregulated kidney expression of the
4A2
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Figure 2 | Amino-acid sequence identities between members
of the rat and mouse CYP4A gene subfamilies. As detailed in
Nebert et al.,10 gene subfamilies names are capitalized, except for the
mouse subfamilies.
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Cyp4a12 AA o-hydroxylase, and increased the renal biosynth-
esis of pro-hypertensive 20-HETE.35 On the other hand, the
normotensive effects of castration on the Cyp4a14(/) mice
were accompanied by reductions in kidney Cyp4a12 expres-
sion and 20-HETE biosynthetic capacity.35 Conversely, the
pro-hypertensive effects of androgen administration to wild-
type male or female mice were associated with increases in
kidney Cyp4a12 expression and 20-HETE biosynthesis.35
Importantly, and in analogy to Cyp4a14(/) mice, castration
reduces by approximately 50 mm Hg the blood pressure of
hypertensive SHR rats,39 and hypertension is also more severe
in male SHR rats.40 These similarities between the androgen-
sensitive components of SHR hypertension and that of
Cyp4a14(/) mouse supports the original proposal that
the CYP4A P450s contribute to the development of high blood
pressure in adult SHR rats.4,16
An important subset of human hypertension is sexual
dimorphism, that is, more severe in males,41–43 and the
involvement of an altered renal microvasculature in human
hypertension has been reported.41,44 As mentioned, 20-HETE
is a powerful vasoconstrictor,4,5,8 and its effects on renovas-
cular tone served as a basis for its proposed pro-hypertensive
role.4,5,8 Functional analysis showed that male Cyp4a14(/)
mice have an impaired renal microvascular autoregulatory
efficiency and increased renal vascular resistance, presumably
due to increased 20-HETE biosynthesis.35 Impaired afferent
arteriolar autoregulatory capacity and increased renal
vascular resistance have been demonstrated in a number of
hypertensive animal models.45–47 Thus, an increased afferent
arteriole resistance may compromise the excretory capacity of
the Cyp4a14(/) kidney and be the determinant factor of
their systemic high blood pressure. In summary, Cyp4a14-
dependent, androgen-mediated, transcriptional and hemo-
dynamic components are at the center of the hypertensive
phenotype of Cyp4a14(/) mice.
DISRUPTION OF THE MURINE Cyp4a10 GENE CAUSES
DIETARY SALT-SENSITIVE HYPERTENSION
Measurements of blood pressure showed that, at difference
with the Cyp4a14(/) animals, adult male and female
Cyp4a10(/) mice were equally hypertensive,36 and that
lack of a functional Cyp4a10 gene had no effect on plasma
androgens.36 Furthermore, an analysis of kidney Cyp4a12
expression and AA o-hydroxylase activity showed that
hypertensive Cyp4a10(/) and normotensive Cyp4a10(þ /
þ ) mice had similar 20-HETE biosynthetic activities.36
These results demonstrated that Cyp4a10(/) hypertension
was unrelated to changes in overall renal 20-HETE
biosynthesis and the hemodynamic effects of this metabo-
lite.36 Paradoxically, mass spectral quantifications showed
that the levels of urinary epoxygenase metabolites in the
Cyp4a10(/) mice were lower than those in wild-type mice,
pointing to a reduced epoxygenase activity in the Cyp4a10(/
) kidney.36 A role for dietary salt in Cyp4a10(/)
hypertension was identified after feeding Cyp4a10(þ /þ )
and Cyp4a10(/) mice diets containing high and low salt
(either 8 or 0.05% NaCl, w/w, respectively).36 As reported,
Cyp4a10(/) mice on a high salt diet become severely
hypertensive,36 whereas, as shown in Figure 3b, those on a
low salt diet become normotensive.36 Reduced urine volumes
and sodium excretion, as well as an increased free fluid
volume, suggested impairments in sodium excretion and
compensatory increases in plasma volume as potential
causative agents for the Cyp4a10(/) salt-sensitive hyper-
tensive phenotype.36
HYPERTENSIVE Cyp4a10(/) MICE SHOW INCREASES IN THE
GATING ACTIVITY OF THE RENAL EPITHELIAL SODIUM
CHANNEL
The decreased levels of urinary epoxygenase metabolites and
the salt-sensitive nature of the animal’s blood pressure,
suggested a potential role for the EETs in Cyp4a10(/)
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Figure 3 | The lack of a functional Cyp4a10 or Cyp4a14 gene
raises systemic blood pressures in mice. (a) The mean arterial
blood pressures of conscious wild-type and of non-castrated
Cyp4a14(/) (control) and castrated Cyp4a14(/) adult male
knockout mice were measured by means of a carotid artery catheter
exactly as described in Holla et al.35 The blood pressures of wild-type
and Cyp4a14(/) mice were significantly different (Po1 104),
whereas those of wild-type and castrated Cyp4a14(/) mice were
not. Values are averages calculated from measurement carried out
with 38 wild-type, 40 Cyp4a14(/), and 16 castrated Cyp4a14(/)
mice 7s.e.m. (b) The systolic blood pressures of conscious wild-type
and Cyp4a10(/) adult male mice fed diets containing either 0.3%
(normal salt) or 0.05% NaCl (low salt) for 3 weeks were measured by
the tail cuff method exactly as described in Imig et al.28 Values are
averages calculated from measurements carried out on at least 15
wild-type (control wild type) and 15 Cyp4a14(/) (control knockout)
mice on normal salt, and 14 Cyp4a10(/) mice on low salt 7s.e.m.
The blood pressures of control wild type and control Cyp4a10(/)
mice were significantly different (Po1 103), whereas those of
control wild type and Cyp4a10(/) mice on low salt diets were not.
(Data from Holla et al.35 and Nakagawa et al.36)
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hypertension. Previous studies showing that the luminal
addition of EETs to perfused rabbit cortical collecting ducts
(CDs) reduces sodium reabsorption and potassium excre-
tion,25 pointed to the CD epithelial sodium channel (ENaC)
as a target for a putative EET natriuretic, anti-hypertensive,
role. This hypothesis was corroborated by electrophysiology
studies using dissected rat CDs and showing that: (a) AA and
11,12-EET inhibit ENaC activity;48 (b) the AA-dependent
inhibition of ENaC requires metabolism to 11,12-EET;48 and
(c) the CYP2C23 epoxygenase is expressed in the rat CD, and
this segment makes 11,12-EET.48 The effects of the epoxy-
genase metabolite on ENaC gating were unique, as indo-
methacin, a cyclooxygenase inhibitor, had no effects on the
AA elicited responses, nor did 20-HETE mimic the EET
effect.48 Although its contribution to overall tubular sodium
reabsorption is limited, the CD participates in the hormonal-
mediated fine-tuning of plasma and interstitial sodium
concentrations, and ENaC is the rate limiting step in this
physiologically important function.49,50 The importance of
ENaC in the control of systemic blood pressure is demon-
strated by human disorders in which gain of function
mutations in this channel cause severe hypertension.49–52
Three important pieces of evidence identify a role for the
Cyp4a10 gene and the EETs in the in vivo regulation of ENaC
gating activity, distal sodium reabsorption, and the control of
systemic blood pressures. Firstly, patch clamp studies of CDs
from Cyp4a10(þ /þ ) and Cyp4a10(/) mice showed that
a disrupted Cyp4a10 gene causes constitutive ENaC activa-
tion and increases inward sodium currents.36 This is similar
to what is observed in Liddle’s syndrome, a Mendelian form
of human hypertension in which a hyperactive ENaC
increases sodium reabsorption and causes hyperten-
sion.49,51,52 Only in CDs from Cyp4a10(/) mice, does
the addition of AA have no effect on ENaC activity,
suggesting that in these animals the CD has a reduced
11,12-EET synthase capacity.36 Importantly, 11,12-EET in-
hibited ENaC activity, regardless of mouse genotype,36
confirming that disruption of the Cyp4a10 gene does not
alter ENaC intrinsic properties but, rather, the regulation of
its gating activity.36 As mentioned, Cyp4a10(/) show
reductions in urinary EETs,36 however, although EET urine
levels give an estimate of their overall kidney biosynthesis,
they do not provide information regarding their segmental
biosynthesis or origin. Technical and mass spectrometry
sensitivity issues prevents a direct quantification of EETs
present in mouse CDs. Secondly, ligands for the peroxisomal
proliferator-activated-a nuclear receptor have been reported
to upregulate the expression, of the CYP2C23 AA epoxygen-
ase in the rat kidney,24 a functional and structural homolog
of the murine Cyp2c44 epoxygenase.10,53 Treatment of
hypertensive Cyp4a10(/) mice with Wyeth 14,643, a
selective peroxisomal proliferator-activated-a ligand,54 upre-
gulates renal Cyp2c44 expression, increases urine EET
concentrations and normalizes the animals systemic blood
pressures.36 Thus, the hypertensive phenotype of Cyp4a10
(/) mice could be rescued experimentally by inducing the
Cyp2c44 AA epoxygenase and raising renal EET biosynthesis
in vivo.36 These associations between genetically controlled
and/or experimentally induced changes in epoxygenase
expression and activity, and systemic blood pressure support
a role for EETs, as anti-hypertensive mediators3–6,8,36
demonstrate that P450 participates in blood pressure
regulation36 and points to the EETs as endogenous regulators
of ENaC activity.36,48 Thirdly, amiloride is a powerful and
selective inhibitor of ENaC activity and its administration
reduces CD sodium reabsorption and potassium excretion.55
Within a few days of administration, amiloride normalized
the blood pressures of hypertensive Cyp4a10(/) mice to
levels comparable with those of wild-type animals (Fig-
ure 4).36 Furthermore, Cyp4a10(/) mice on amiloride
remained normotensive even after the administration of 2%
NaCl in their drinking water (Figure 4),36 and the blood
pressure effects of amiloride were reversible, since upon its
removal, the hypertensive phenotype of the Cyp4a10(/)
animals was restored (Figure 4).36 In summary, these results
identified ENaC as the molecular target of the hypertensive
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Figure 4 | Amiloride normalizes the systolic blood pressures of
Cyp4a10(/) knockout mice. Groups of adult male wild-type and
Cyp4a10(/) mice were fed standard mouse chow, and allowed free
access to water (days 1–4), or to water containing either amiloride
(50mg/ml) (days 8–21), a mixture of amiloride (50 mg/ml) and NaCl
(2% w/v) (days 22–28), or just NaCl (2% w/v) (days 29–34). The
animal’s systolic blood pressures were measured as in Nakagawa
et al.36 There were no significant changes in the blood pressure of
wild-type mice during the different treatment regimes, nor were
there differences between the wild-type and Cyp4a10(/) mice
treated with amiloride, or amiloride in 2% NaCl. The blood pressures
of the Cyp4a10(/) mice drinking water or a 2% solution of NaCl
were significantly different to those of wild-type animals under
similar treatment regimes (Po1 103). The blood pressures of
Cyp4a10(/) mice drinking a solution of amiloride were significantly
different to that of Cyp4a10(/) mice drinking water (Pp 103).
Shown are averages of daily blood pressure measurements carried
out on at least five wild-type and five Cyp4a10(/) animals7s.e.m.
(Data from Nakagawa et al.36)
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phenotype brought about by the disruption of the Cyp4a10
gene and demonstrated that altered tubular transport is the
causative agent of the Cyp4a10(/) hypertensive pheno-
type.36 Importantly, the documented ability of 11,12-EET to
regulate ENaC gating in real time36,48 indicates that this
eicosanoid may function as an endogenous natriuretic agent.
Abundant functional data, and the characterization of
Cyp4a14(/) and Cyp4a10(/) mice as hypertensive have
identified a key physiological role for these P450s in the
regulation of renal hemodynamics and tubular sodium
transport, and in the pathophysiology of androgen and
salt-sensitive hypertension, respectively.35,36 Additionally,
these studies identify members of the human CYP4A and
CYP2C gene subfamilies, as candidate genes for studies of the
molecular basis of human hypertension. The human genome
contains two highly homologous CYP4A genes, that is,
CYP4A22 and CYP4A11,8,10 and four CYP2C genes, that is,
CYP2C8, CYP2C9, CYP2C18, and CYP2C19.10 CYP4A11
codes for an active kidney 20-HETE synthase,56 CYP4A22
codes for a non-functional protein, and is undetectable in
kidney,56 and CYP2C8 has been identified as a renal AA
epoxygenase.57 Importantly, two independent studies have
associated a functional variant of the human CYP4A11 gene
with essential hypertension58,59 and altered 20-HETE-asso-
ciated natriuresis has been linked to human salt-sensitive
hypertension.60 Thus, genetic rat models of hypertension,
genetic targeting of P450 in mice, and human studies point
to the importance of AA P450 metabolites in water and
electrolyte homeostasis and blood pressure regulation.
With few exceptions, the molecular bases of the most
common forms of human hypertension are yet to be defined
and thus, the early diagnosis and clinical management of this
devastating disease remains challenging and mostly sympto-
matic. This situation reflects the complexity of a disease in
which multiple environmental and genetic factors, as well as
coexisting conditions may contribute to a multifaceted
etiology. The studies summarized above identify a concep-
tually novel approach for studies of the molecular basis of
human hypertension, and provide an experimental founda-
tion for future clinical studies of the roles of these enzymes in
human hypertension. Indeed, the efforts of several research
groups are changing long-held views regarding the roles that
P450s play in the metabolism of endogenous substrates and
the regulation of cell, organ, and body physiology, vis-a-vis,
their established roles in the metabolism and detoxification
of foreign chemicals and drugs.
CONCLUSION AND FUTURE DIRECTIONS
There is now convincing evidence of a role for the
microsomal AA monooxygenase in renal physiology and
blood pressure regulation, as well as for them as potential
contributors to the pathophysiology of subsets of human
hypertension. Two additional properties of the P450-derived
eicosanoids5–7,9,30,61,62 are becoming of great interest. These
include potential functional roles of: (a) EETs and 20-HETE
as regulators of ion channel activity and, in particular, the
physiological significance of their effects on vascular Caþ þ
activated Kþ channels,5,30 and roles as endothelium-derived
hyperpolarizing factor and anti-endothelium-derived hyper-
polarizing factor mediators;5,30 and (b) EETs as mitogenic
and angiogenic mediators,3,9,61,62 and their use as potential
targets for the development of novel anti-angiogenic
approaches for cancer therapy. Ongoing efforts in all these
areas of interest hold the promise of providing new avenues
for the understanding of basic cell, organ, and body
physiology. Among the many issues that remain outstanding
in this area of research, we include: (a) the characterization of
the molecular mechanisms responsible for EET-mediated
effects on ion membrane, ion permeability, and ion channel
activity; (b) the study of signaling mechanisms for EETs and
20-HETE and the characterization of putative membrane
bound receptors for these eicosanoids; (c) the biochemical,
molecular, and functional characterization of organ/tissue/
cell-specific AA monooxygenases, and of their human
homologues; (d) the identification and molecular characteri-
zation of the mechanism by which Cyp4a isoforms regulate
gene transcription; (e) the identification and molecular
characterization of mechanisms that control the expression
of AA monooxygenase in a organ/tissue/cell-specific manner;
and (e) the analysis of correlations between human
pathophysiological conditions and alterations in the genes
coding for P450 AA epoxygenases and/or o-hydroxylases.
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